DE60232290D1 - Kontrollierte Auflösung von Wirkstoffen - Google Patents
Kontrollierte Auflösung von WirkstoffenInfo
- Publication number
- DE60232290D1 DE60232290D1 DE60232290T DE60232290T DE60232290D1 DE 60232290 D1 DE60232290 D1 DE 60232290D1 DE 60232290 T DE60232290 T DE 60232290T DE 60232290 T DE60232290 T DE 60232290T DE 60232290 D1 DE60232290 D1 DE 60232290D1
- Authority
- DE
- Germany
- Prior art keywords
- active substances
- controlled dissolution
- dissolution
- controlled
- substances
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
- A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28244301P | 2001-04-09 | 2001-04-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60232290D1 true DE60232290D1 (de) | 2009-06-25 |
Family
ID=23081541
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60232290T Expired - Lifetime DE60232290D1 (de) | 2001-04-09 | 2002-03-22 | Kontrollierte Auflösung von Wirkstoffen |
Country Status (6)
Country | Link |
---|---|
US (1) | US7153497B2 (de) |
EP (1) | EP1250937B1 (de) |
JP (1) | JP4295951B2 (de) |
KR (1) | KR100905453B1 (de) |
DE (1) | DE60232290D1 (de) |
TW (1) | TWI242446B (de) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060115529A1 (en) * | 2003-05-07 | 2006-06-01 | Seonghoon Jeong | Fast-melting tablets having taste-masking and sustained release properties |
US20050036977A1 (en) * | 2003-08-11 | 2005-02-17 | Dilip Gole | Taste-masked resinate and preparation thereof |
US20050265955A1 (en) * | 2004-05-28 | 2005-12-01 | Mallinckrodt Inc. | Sustained release preparations |
CA2645855C (en) | 2006-03-16 | 2015-02-03 | Tris Pharma, Inc. | Modified release formulations containing drug-ion exchange resin complexes |
US8187636B2 (en) | 2006-09-25 | 2012-05-29 | Atlantic Pharmaceuticals, Inc. | Dosage forms for tamper prone therapeutic agents |
EP2164631A4 (de) * | 2007-05-30 | 2013-08-21 | Neos Therapeutics Lp | Modifizierung der arzneistofffreisetzung in suspensionen von ionischen harzsystemen |
FR2947276B1 (fr) * | 2009-06-24 | 2012-10-26 | Seppic Sa | Composition cosmetique a base de resines echangeuses d'ions chargees avec des lipoaminoacides |
US8623409B1 (en) | 2010-10-20 | 2014-01-07 | Tris Pharma Inc. | Clonidine formulation |
EP2725072B1 (de) * | 2012-10-25 | 2015-07-22 | Rohm and Haas Company | Beseitigung von aldehyd mit porösen aminfunktionsharzen |
US8999393B1 (en) | 2013-01-09 | 2015-04-07 | Edgemont Pharmaceuticals Llc | Sustained release formulations of lorazepam |
US11590228B1 (en) | 2015-09-08 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine compositions |
AU2017423069B2 (en) | 2017-07-11 | 2020-10-22 | Dow Global Technologies Llc | Aqueous dispersion and aqueous coating composition comprising the same |
US11590081B1 (en) | 2017-09-24 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine tablets |
US11918689B1 (en) | 2020-07-28 | 2024-03-05 | Tris Pharma Inc | Liquid clonidine extended release composition |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1585174A (en) * | 1976-06-16 | 1981-02-25 | Ici Ltd | Separation of sugars from mixtures |
CH655507B (de) * | 1983-01-12 | 1986-04-30 | ||
US4898729A (en) * | 1983-12-09 | 1990-02-06 | Euroceltique, S.A. | Treatment of hypertension, compounds and compositions for antihypertension and diuresis |
US5026559A (en) * | 1989-04-03 | 1991-06-25 | Kinaform Technology, Inc. | Sustained-release pharmaceutical preparation |
GB9005498D0 (en) * | 1990-03-12 | 1990-05-09 | Beecham Group Plc | Composition |
US5316772A (en) * | 1990-12-19 | 1994-05-31 | Solvay & Cie, S.A. (Societe Anonyme) | Bilayered oral pharmaceutical composition with pH dependent release |
GB9402029D0 (en) * | 1994-02-03 | 1994-03-30 | Smithkline Beecham Plc | Novel formulation |
-
2002
- 2002-03-22 DE DE60232290T patent/DE60232290D1/de not_active Expired - Lifetime
- 2002-03-22 EP EP02252070A patent/EP1250937B1/de not_active Expired - Lifetime
- 2002-03-26 US US10/107,898 patent/US7153497B2/en not_active Expired - Lifetime
- 2002-03-27 TW TW091106011A patent/TWI242446B/zh not_active IP Right Cessation
- 2002-04-04 KR KR1020020018458A patent/KR100905453B1/ko active IP Right Grant
- 2002-04-09 JP JP2002106400A patent/JP4295951B2/ja not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
JP4295951B2 (ja) | 2009-07-15 |
EP1250937A3 (de) | 2003-09-24 |
EP1250937B1 (de) | 2009-05-13 |
US20020146384A1 (en) | 2002-10-10 |
US7153497B2 (en) | 2006-12-26 |
KR100905453B1 (ko) | 2009-07-02 |
KR20020079473A (ko) | 2002-10-19 |
JP2003012562A (ja) | 2003-01-15 |
EP1250937A2 (de) | 2002-10-23 |
TWI242446B (en) | 2005-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60220661D1 (de) | Transdermales pflaster zur verabreichung von fentanyl | |
DE60333294D1 (de) | Kontrollierte verabreichung von arzneien | |
DE60121953D1 (de) | Herstellungsverfahren von arzneizubereitungen | |
ATE370938T1 (de) | Pro-pharmakon von cox-2-inhibitoren | |
ATE298634T1 (de) | Flüssigkeitszerstäuber | |
PT1239733E (pt) | Combinacoes de substancias activas fungicidas | |
DE60211601D1 (de) | Bereitstellung von positionsabhängigen Inhalten | |
DE50212273D1 (de) | Pharmazeutische salze von 1-phenyl-3-dimethylamino-propan-verbindungen | |
DE60219292D1 (de) | Pyrazolderivate zur behandlung von hiv | |
ATE296619T1 (de) | Feste orale dosierungsform von simethicon | |
ATE323661T1 (de) | Behandlung von mineralischen stoffen | |
ATE411332T1 (de) | 3'-prodrugs von 2'-deoxy-beta-l-nukleosiden | |
DK1395242T3 (da) | Flydende farmaceutisk sammensætning | |
DE60201859D1 (de) | Pharmazeutische Verwendung von N-Carbamoylazol-Derivate | |
ATE401908T1 (de) | Pharmazeutische zusammensetzungen von erythropoietin | |
DE60232290D1 (de) | Kontrollierte Auflösung von Wirkstoffen | |
DE60025627D1 (de) | Pharmazeutische lösung von levosimendan | |
IT1324892B (it) | Miscele di agenti stabilizzanti | |
DE50003755D1 (de) | Satz von schmuckstücken | |
DE60000343T2 (de) | Stabilisierung von isothiazolonen | |
IT1324893B (it) | Miscele di agenti stabilizzanti | |
DE60141146D1 (de) | Adressierung von multistabilen nematischen fluessigkristallvorrichtungen | |
ATE254929T1 (de) | Oralverabreichbare lösung von prucaloprid | |
DE60103685D1 (de) | Behandlung von Poriomania | |
PT1150568E (pt) | Combinacoes de substancias activas fungicidas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |